drug · antibody
patient view →glofitamab
Marketedupdated 2mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and diffuse large b-cell lymphoma and 6 investigational indications.
indications
investigational
DLBCL
targets
B-lymphocyte antigen CD20T cell surface glycoprotein CD3
all catalysts(3)
approval · 3
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that